CA3045743A1 — Ophthalmic composition for treatment of dry eye disease
Assigned to Novaliq GmbH · Expires 2018-06-28 · 8y expired
What this patent protects
The invention provides pharmaceutical compositions comprising about 0.05 to 0.1 % (w/v] cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kit…
USPTO Abstract
The invention provides pharmaceutical compositions comprising about 0.05 to 0.1 % (w/v] cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.
Drugs covered by this patent
- Sandimmune (cyclosporine) · Novartis AG (originally Sandoz)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.